Axalbion will start a proof of concept study in patients with chronic cough

Axalbion will soon start recruitment for a Phase 2 study to assess the efficacy and safety of AX-8 in patients with chronic cough.

This is a randomized, double-blind, placebo-controlled, crossover, multicenter study of AX-8 in participants with unexplained or refractory chronic cough designed to evaluate the effectiveness of AX-8 in reducing cough frequency.
https://www.clinicaltrials.gov/ct2/show/NCT04866563?term=04866563&draw=2&rank=1